Kwangdong will pay Ocugen up to $7.5 million for rights to sell OCU400 in South Korea, plus further milestone payments and royalties on net sales.

Vyjuvek was approved in 2023, initially for patients at least six months of age, and could only be applied by healthcare professionals.

Investigators have used base editing to create a treatment for multisystemic smooth muscle dysfunction syndrome, which has ...

The firm's commercialization push is fueled by $35.6 million from a recent Series C financing and a $15.5 million ...

Funded through a $17 million NIH grant, the program will try six strategies to combat HIV and advance the most promising.

The agency said it will accept data from single-arm trials in its newly released Rare Disease Evidence Principles, but ...

Autonomous AI tools have great potential in supporting precision medicine, but developers are still figuring out how to deploy them in patient care.

Some feel the guidance may encourage consistent follow-up of overall survival after accelerated approvals, but others remain focused on speeding new drugs to patients.

The firm has voluntarily halted the SYNRGY study so it can investigate what caused the patient's death and will assess next steps based on the findings.

The firm will use the proceeds to fund clinical trials in thyroid eye disease, diabetes, geographic atrophy, and other chronic diseases.

Phase II/III data showed that advanced gastric cancer patients on anbenitamab and chemotherapy fared better than those on standard therapy.

The firm said it will enroll more ovarian cancer patients in its ongoing Phase II trial to gather data for a regulatory submission for rezatapopt to the FDA.